Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L'Oreal contributes to animal testing alternative

This article was originally published in The Rose Sheet

Executive Summary

French beauty firm and assay developer Hurel Corporation are in the research and development stage of an in vitro test for potential skin allergic reactions called the "Allergy Test on a Chip." The device is designed as a substitute for the animal test known as the local lymph node assay, currently accepted by regulatory agencies as a standard means of evaluating potential responses. The test comprises reconstructed human skin, a cell culture capable of stimulating a human immune system response and a means of signaling an immune system response from the skin, the firms say. The collaboration has already hit its first milestone: demonstrating the microfluidic signaling component of the device. If globally adopted, Allergy Test on a Chip "may dramatically reduce the use of animal tests in safety evaluation," the companies say, adding it also has commercial potential
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS016673

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel